Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders by Hendrik Wesseling et al.
Wesseling et al. Molecular Autism 2014, 5:38
http://www.molecularautism.com/content/5/1/38RESEARCH Open AccessIntegrative proteomic analysis of the NMDA NR1
knockdown mouse model reveals effects on
central and peripheral pathways associated with
schizophrenia and autism spectrum disorders
Hendrik Wesseling1, Paul C Guest1, Chi-Ming Lee2, Erik HF Wong2, Hassan Rahmoune1 and Sabine Bahn1,3*Abstract
Background: Over the last decade, the transgenic N-methyl-D-aspartate receptor (NMDAR) NR1-knockdown mouse
(NR1neo−/−) has been investigated as a glutamate hypofunction model for schizophrenia. Recent research has now
revealed that the model also recapitulates cognitive and negative symptoms in the continuum of other psychiatric
diseases, particularly autism spectrum disorders (ASD). As previous studies have mostly focussed on behavioural
readouts, a molecular characterisation of this model will help to identify novel biomarkers or potential drug targets.
Methods: Here, we have used multiplex immunoassay analyses to investigate peripheral analyte alterations in serum of
NR1neo−/− mice, as well as a combination of shotgun label-free liquid chromatography mass spectrometry, bioinformatic
pathway analyses, and a shotgun-based 40-plex selected reaction monitoring (SRM) assay to investigate altered molecular
pathways in the frontal cortex and hippocampus. All findings were cross compared to identify translatable findings
between the brain and periphery.
Results: Multiplex immunoassay profiling led to identification of 29 analytes that were significantly altered in sera of
NR1neo−/− mice. The highest magnitude changes were found for neurotrophic factors (VEGFA, EGF, IGF-1), apolipoprotein
A1, and fibrinogen. We also found decreased levels of several chemokines. Following this, LC-MSE profiling led to
identification of 48 significantly changed proteins in the frontal cortex and 41 in the hippocampus. In particular, MARCS,
the mitochondrial pyruvate kinase, and CamKII-alpha were affected. Based on the combination of protein set enrichment
and bioinformatic pathway analysis, we designed orthogonal SRM-assays which validated the abnormalities of proteins
involved in synaptic long-term potentiation, myelination, and the ERK-signalling pathway in both brain regions. In
contrast, increased levels of proteins involved in neurotransmitter metabolism and release were found only in the frontal
cortex and abnormalities of proteins involved in the purinergic system were found exclusively in the hippocampus.
Conclusions: Taken together, this multi-platform profiling study has identified peripheral changes which are potentially
linked to central alterations in synaptic plasticity and neuronal function associated with NMDAR-NR1 hypofunction.
Therefore, the reported proteomic changes may be useful as translational biomarkers in human and rodent model drug
discovery efforts.
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The transgenic NR1-knockdown (NR1neo−/−) mouse consti-
tutively expresses only 5 to 10% of the essential N-methyl-
D-aspartate receptor (NMDAR) NR1 subunit [1]. The
NMDAR is crucial in neuronal development and physi-
ology, and decreased levels or altered function of this recep-
tor have been associated with the pathophysiology of
schizophrenia (SZ) [2-5]. Consequently, the NR1neo−/−
mouse has been widely used as a genetic model for intrinsic
NMDAR hypofunction in preclinical drug discovery efforts.
NR1neo−/− mice display hyperlocomotion and increased
stereotypic behaviour, which represent standard behavioural
readouts for the evaluation of animal models of SZ. These
behavioural effects can be attenuated by the typical anti-
psychotic drug haloperidol, a potent highly specific D2-
dopamine receptor antagonist [6], and by the atypical
antipsychotic drug clozapine [1], which affects a broader
spectrum of neurotransmission systems [7,8]. In addition to
these behavioural changes, NR1neo−/− mice also show sig-
nificant impairments in spatial cognitive performance [9],
reduced social interaction, escape behaviours, and actively
avoid interaction with intruder males. Furthermore,
NR1neo−/− males have been reported to be infertile due to
their abnormal social behaviour. However, administration
of clozapine has been found to ameliorate all of these
symptoms [1], which are thought to predominantly reflect
the negative and cognitive symptoms of SZ.
Interestingly, recent studies investigating the NR1neo−/−
mouse identified behavioural and electrophysiological
deficits relevant to all core symptoms of autism
spectrum disorders (ASD) [10,11]. Further, clinical ASD
symptomatology, including reduced prepulse-inhibition,
auditory-evoked response N1 latency, and reduced
gamma synchrony was observed in the NR1neo−/− mouse
[12]. NMDAR NR1 subunit knockout in parvalbumin-
positive interneurons resulted in an ASD-like pheno-
type [13] with impaired self-care and sociability [14] in
the absence of depression-related behaviours [15]. In
addition, NMDAR and glutamate abnormalities have
been identified in various brain disorders, such as
major depressive disorder [16,17] and ASD [18-20],
which are characterized by negative symptom domains.
The abovementioned behavioural data now supports
the hypothesis of a potential role of impaired NMDAR
function in the continuum of negative symptom pheno-
types of a range of psychiatric disorders, including core
features of autism [21].
Given these similarities, the primary objective of this
study was to identify molecular signatures in the
NR1neo−/− mouse model and to gain insights into the
downstream molecular effects of glutamate dysfunction. A
combination of three proteomic platforms was employed
to explore a wide range of protein abundance changes
in brain tissue and serum samples from the NR1neo−/−mouse model. Specifically, multiplex immunoassay pro-
filing was used to assess serum changes given the high
sensitivity of this method for quantification of low abun-
dance circulating proteins such as cytokines, hormones,
and growth factors. Label-free liquid chromatography –
mass spectroscopy in expression mode (LC-MSE) analysis
was used as this allows unbiased screening of approxi-
mately 1,000 proteins in a single extract and targets pro-
teins, such as membrane receptors, nuclear factors,
mitochondrial proteins, and cytoplasmic molecules, all of
which have been implicated in psychiatric disorders.
Finally, SRM mass spectrometry was used to target spe-
cific classes of proteins with greater sensitivity than the
LC-MSE approach. A secondary goal was to investigate
whether changes in protein levels in serum can be
linked to glutamatergic brain dysfunction, thus evaluat-




The NR1neo−/− mice [1,22,23] were obtained from the
laboratory of Dr. Beverly Koller (The University of North
Carolina at Chapel Hill) and a breeding colony was estab-
lished at AstraZeneca Pharmaceuticals LP (Wilmington
DE 19850, USA). All breeding and testing procedures
were conducted in strict compliance with the “Guide for
the Care and Use of Laboratory Animals” (Institute of
Laboratory Animal Resources, National Research Council,
1996) and approved by the Institutional Animal Care and
Use Committee of the University of North Carolina and
AstraZeneca R&D Montréal. The breeding and genotyp-
ing was performed as previously described [24-27]. It
involved three populations of mice: NR1neo+/− hetero-
zygotes maintained on C57BL/6 background (Jackson
Laboratory), NR1neo+/− heterozygotes maintained on 129/
SvEv background (Taconic Farm), and an intercross
between female C57BL/6 NR1neo+/− and male 129/SvEv
NR1neo+/− to generate the F1 male NR1neo−/− and wildtype
(WT) mice that were analysed in this study. Homozygotes
carrying the NR1 hypomorphic mutation do not breed
effectively. Therefore, the mutant homozygotes had to
be generated by cross-breeding heterozygotic mice. The
NR1 hypomorphic mutation could not be induced in
pure C57BL/6 J or 129SvEv mice, because the mutants
did not gain weight at the same rate as WT mice and
the frequency of mutants born was less than expected.
To overcome these problems, the strategy of breeding
F1 hybrids was developed to generate the NR1neo/neo
mice [27]. Therefore, the progeny from the intercross
were genetically identical F1 hybrids with the exception
at NR1 locus: 50% NR1neo+/−, 25% NR1neo−/−, and 25%
WT. The following primers were used for genotyping:
NR1 (+) fwd primer (intron 20) 5′TGA GGG GAA
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GCT TCC TCG TGC TTT ACG GTA T3′; and NR1
common reverse primer (intron 20) 5′AAG CGA TTA
GAC AAC TAA GGG T3′. Mice were housed on a
12 h light/dark cycle with access to food and water ad
libitum. Mice (3 to 4 months old) were killed according
to schedule, decapitated, and trunk blood was collected
in ice-chilled tubes containing EDTA and centrifuged
at 1,100 g, 4°C, for 15 min. The serum was immediately
separated and stored frozen at −80°C for later use.
Brains were dissected on ice. Frontal cortex and hippo-
campus tissue were stored at −80°C.
Multiplex immunoassay profiling
Serum samples were analyzed using a rodent multiana-
lyte profiling platform comprising multiplexed immuno-
assays of 75 analytes (Additional file 1: Table S2) in a
Clinical Laboratory Improved Amendments (CLIA)-cer-
tified laboratory at Myriad-RBM (Austin, TX, USA), as
described previously [28]. Immunoassays were calibrated
using duplicate standard curves for each analyte and raw
intensity measurements converted to protein concentra-
tions using proprietary software. Multiplexed calibrators
(eight levels per analyte) and controls (three levels per
analyte) are developed to monitor key performance pa-
rameters, such as a lower limit of quantification, preci-
sion, cross-reactivity, linearity, spike-recovery, dynamic
range, matrix interference, freeze-thaw stability, and
short-term sample stability are established for every
assay as described by the manufacturer (http://www.
myriadrbm.com/technology/data-quality/). Data analyses
were performed using the statistical software package R
(http://www.r-project.org) and the analyte levels were
determined. Analyses were conducted under blinded
conditions with respect to sample identities and samples
were analyzed in random order to avoid any sequential
biases.
Sample preparation
Tissue samples were added to fractionation buffer con-
taining 7 M urea, 2 M thiourea, 4% CHAPS, 2% ASB14,
70 mM DTT, and protease inhibitor at a 5:1 (v/w) ratio
[29]. Samples were sonicated (10 sec, 2 cycles) and vor-
texed at 4°C for 30 min. Samples were then centrifuged
at 17,000 g at 4°C. Protein concentrations of the lysates
were determined using a Bradford assay (Bio-Rad;
Hemel Hempstead, UK). Approximately 100 μg was pre-
cipitated using acetone. After dissolving the precipitate
in 50 mM ammonium bicarbonate, reduction of sulfhy-
dryl groups were performed with 5 mM DTT at 60°C for
30 min and alkylation was carried out using 10 mM
iodacetamide, incubated in the dark at 37°C for 30 min,
and subsequently digested using trypsin at a 1:50 (w/v)
ratio for 17 h at 37°C. Reactions were stopped by theaddition of 8.8 M HCl in a 1:60 (w/w) ratio. Quality con-
trol samples were prepared to monitor machine and
preparation performance.Label-free LC-MSE analysis
Brain tissue samples were analysed individually in tech-
nical duplicates. Splitless nano-ultra-performance liquid
chromatography (UPLC) (10 kpsi nanoAcquity; Waters
Corporation, Milford, MA, USA), was coupled online
through a New Objective nanoESI emitter (7 cm length,
10-mm tip; New Objective, Woburn, MA, USA) to a
Waters Q-TOF Premier mass spectrometer. Data were
acquired in expression mode (MSE) and the total con-
tinuous run time was 8 days. The procedure, quality as-
sessment, and data processing were performed as
described previously [30]. LC-MSE data were processed
by the ProteinLynx Global Server (PLGS v.2.4 Waters,
Milford, MA, USA) for ion detection, extraction, and
identification using an ion accounting algorithm [31].
The Swiss-Prot rodent reference proteome database
(2011–2013) was used for protein identification searches.
To control the false discovery rate (FDR), data were
searched against a decoy database, which was the rando-
mised version of the database mentioned above to
conserve amino acid frequencies. The FDR was set at
the default maximum rate of 4%, as applied before
[32-35]. The search parameters were (i) enzyme = trypsin,
(ii) fixed modification = carbamidomethylation of cyste-
ines, (iii) variable modifications = oxidation of methionine
and phosphorylation at serine, threonine, or tyrosine resi-
dues, (iv) initial mass accuracy tolerances = 10 ppm for
precursor ions and 20 ppm for product ions, and (v) one
missed cleavage allowed. In addition, the following criteria
were used for protein identification: (i) ≥3 fragment ions
per peptide, (ii) ≥7 fragment ions per protein, and (iii) ≥1
peptide per protein. Raw data and PLGS search results
were imported into the Rosetta Elucidator software (build
3.3.0.1.SP3.19, Rosetta Biosoftware; Seattle, WA, USA).
Elucidator performed retention time (RT) and mz/charge
alignment, feature identification, and extraction for all
samples using the Rosetta PeakTeller algorithm. Dynamic
background subtraction, smoothing in RT, and m/z di-
mension and isotopic region creation for peak-matching
across all runs were calculated using an RT correction of
4 min at the maximum. A single data file was randomly
chosen as the master, and all other sample files were
aligned to the master in form of a dynamic RT shift. This
procedure allowed the improved identification of peptides
and proteins in each sample by taking the available data of
all samples into account. Features were filtered for high
score and normalized based on total ion current. Only
peptides detected in both replicates and in >80% of sam-
ples were included in further analysis.
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MSstats package [36] based on linear mixed-effects models
on the peptide intensities, following log2 transformation
and exclusion of intensity values deviating more than three
standard deviations from the mean of each group (<1% of
total data). Proteins were identified by at least two peptides.
The P values were adjusted to control the FDR at a cut-off
of 0.05 following the Benjamini-Hochberg procedure [37].
Protein set enrichment analysis
Protein set enrichment analysis was carried out as previ-
ously described [38,39]. Significantly changed proteins
were partitioned into three bins, according to their pre-
dicted fold-change (FC): FC <1.0; FC >1.0, and 1 < FC
<1. The R package database org.Mm.eg.db version 2.8.0
was used for gene ontology (GO) term annotation based
on entrez gene identifiers. Significant overrepresentation
of an annotated GO term per bin was determined by the
GOstats package [40]. For each bin, P values for the GO
categories [41] “biological pathway” and “cellular com-
partment” were calculated by a conditional hypergeo-
metric test using the entire detected proteome as a
background. These tests accounted for the hierarchical
structure of the GO terms by first testing the “child
terms” of any given GO category and filtering signifi-
cantly enriched proteins prior to analysis of the “parent
terms”, as described previously [42]. This prevented the
identification of directly-related GO terms with a con-
siderable overlap of assigned proteins. GO terms with
no significant enrichment in any bin (P >0.05) and GO
terms with less than two annotated proteins were re-
moved. The remaining P values greater than 0.05 were
replaced by a conservative P value of 1. P values were re-
placed by their negative logarithm to the base of ten and
then converted to z-scores within their proteomic com-
parison for every remaining GO term. Finally, one-way
hierarchical clustering using “Euclidean distance” as dis-
tance function and the “Average Linkage Clustering”
method available in the software Genesis [43], was per-
formed on all significantly enriched GO terms. The same
enrichment analysis was repeated using KEGG pathway
annotation in order to provide an independent in silico
validation of our findings.
Label-based selected reaction monitoring (SRM) mass
spectrometry
Abundance alterations of a panel of 39 candidate proteins
implicated in the pathway analysis of the NR1neo−/− mouse
(see results section) were measured using targeted SRM
mass spectrometry on a Xevo TQ-S mass spectrometer
(Waters Corporation) coupled online through a New Ob-
jective nanoESI emitter (7 cm length, 10-mm tip; New
Objective) to a nanoAcquity UPLC system (Waters Cor-
poration). The system was comprised of a C18 trappingcolumn (180 μm× 20 mm, 5 μm particle size) and a C18
BEH nano-column (75 μm× 200 mm, 1.7 mm particle
size). The separation buffers were (A) 0.1% formic acid
and (B) 0.1% formic acid in acetonitrile. For separation of
peptides, the following 48-min gradient was applied: 97/
3% (A/B) to 60/40% B in 30 min; 60/40% to 15/85% in
2 min; 5 min at 15/85%; returning to the initial condition
in 1 min. The flow rate was 0.3 μL/min and the column
temperature was 35°C.
SRM assays were developed following a general high-
throughput strategy [44]. For method refinement, initially
up to 12 unique peptides ranging from 6 to 20 amino acids
in length, containing tryptic ends and no miscleavages were
chosen for each of the selected proteins. All peptides con-
taining amino acids prone to undergo modifications (e.g.,
Met, Trp, Asn, and Gln), potential ragged ends, lysine/ar-
ginine followed by proline or bearing the NXT/NXS glyco-
sylation motif were generally avoided and only selected
when no other options were available [45]. Peptides were
checked by Protein BLAST (http://blast.ncbi.nlm.nih.gov/
Blast.cgi) searches to ensure uniqueness. For method re-
finement, up to 12 transitions per peptide were tested in
SRM mode. Transitions were calculated using Skyline ver-
sion 1.2.0.3425 [46] and corresponded to singly charged y-
ions from doubly or triply charged precursors, in the range
of 350 to 1,250 Da. Transitions were selected based on soft-
ware internal predictions, discovery proteomics data, and
spectral data available through the Human National Insti-
tute of Standards and Technology spectral libraries [47].
Method refinement was performed on quality control sam-
ples. For the final SRM assays, 2 to 3 peptides with the
maximal intensities and highest spectral library similarity
(dotp) per protein were selected. A further development
step, analysing heavy-label spiked quality control samples in
scheduled SRM mode, was used to confirm identity via co-
elution, extract the optimal fragment ions for SRM analysis,
obtain accurate peptide retention times, and optimize colli-
sion energy and cone voltage for the quantification run ap-
plying skyline software (MacCoss Lab Software; Seattle,
WA, USA) [46]. Heavy labelled forms of these selected pep-
tides (spiketides L) were chemically synthesized via SPOT
synthesis (JPT Peptide Technologies GmBH, Berlin,
Germany). The final transitions, collision energy, and reten-
tion time windows used for each peptide can be found in
the supplementary information (Additional file 2: Table S1).
Quantitative SRM measurements comparing NR1neo−/−
and WT mice were performed in scheduled SRM acquisi-
tion mode with the optimized parameters defined during
the assay refinement. For each target peptide a heavy iso-
tope labelled internal standard (JPT Peptide Technologies
GmbH) was spiked in the peptide mixture for accurate
quantification and identification. All SRM functions had a
2 min window of the predicted RT and scan times were
20 ms, which ensured a dwell time of over 5 ms per
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methods using Skyline software. This was done because of
scheduling, assay development progress, and assay availabil-
ity reasons. For each peptide, at least three transitions were
monitored for the heavy and light version. Samples were
run randomized and blocked [48] in triplicates and blanks
and quality control peptide injections (yeast alcohol de-
hydrogenase, Additional file 2: Table S1) were performed
alternating after every biological replicate. Resulting SRM
data was analyzed using skyline and protein significance
analysis was performed using SRMstats [49]. In the first
step, data pre-processing was performed by transforming
all transition intensities into log2-values. Then a constant
normalization was conducted based on reference transi-
tions for all proteins, which equalized the median peak in-
tensities of reference transitions from all proteins across all
MS runs and adjusted the bias to both reference and en-
dogenous signals. Protein level quantification and testing
for differential abundance among NR1neo−/− and WT
mouse groups were performed using the linear mixed-
effects model implemented in SRMstats. The scope of
validity of our conclusions was restricted to the specific
biological replicates in the experiments. Each protein was
tested for abundance differences between NR1neo−/− and
WT mouse. The P values were adjusted to control the
FDR at a cut-off of 0.05 according to Benjamini and
Hochberg [37].
Results
Serum characterisation – Quantitative serum
immunoassay profiling
We evaluated the peripheral adaption to the systemically
reduced NMDAR-NR1 expression by analysing 75 ana-
lytes (Additional file 1: Table S2) in serum using a multi-
plex immunoassay platform. After principal component
analysis data quality assessment and outlier filtering, the
analysis resulted in the identification of 29 significantly
altered molecules (P <0.05) (Table 1). The most promin-
ent changes included a 17-fold increase in apolipopro-
tein A1 (ApoA1), a 13-fold increase in fibrinogen, and
an 8-fold increase in vesicular endothelial growth factor
A (VEGF), as well as a 6-fold decrease in insulin-like
growth factor 1 (IGF-1). The protein levels of all identi-
fied chemokines (Ccl12, Ccl11, Xcl1, Ccl7, and Ccl22)
were significantly decreased.
Brain characterisation – quantitative LC-MSE proteomic
profiling of frontal cortex and hippocampus
LC-MSE analysis resulted in the identification of 11,345
distinct peptides (563 proteins) in the frontal cortex and
14,775 distinct peptides (883 proteins) in the hippocam-
pus after filtering the data using the criteria described in
the Materials and Methods section. In the frontal cortex,
48 proteins were found to be significantly altered bymore than 10% (Figure 1, Additional file 3: Table S3).
In the hippocampus, 41 proteins showed significant
changes using the same criteria.
The EH domain-containing protein 4 (EHD4), adenylo-
succinate synthetase isozyme (PURA1), guanine nucleotide-
binding protein G(I)/G(S)/G(O) subunit gamma 12
(GBG12), myristoylated alanine-rich C-kinase substrate
(MARCS), and selenium-binding protein 2 (SBP2) were
identified as most significantly altered in the frontal cortex
and synaptonemal complex protein 3 (SYCP3), asparagine
synthetase [glutamine-hydrolyzing] (ASNS), NADH de-
hydrogenase 1 alpha subcomplex subunit 4 (NDUA4), and
complexin 1 (CPLX1) were most significantly changed in
the hippocampus. CaM kinase II subunit alpha (KCC2A)
was detected as highly significantly reduced in both brain re-
gions but showed a 10% decrease.
Quantitative LC-MSE proteomic profiling-based pathway
analysis
Ingenuity pathway analysis (IPA) was performed using all
significantly changed proteins (P* <0.05) in the frontal cor-
tex (142 proteins) and hippocampus (227 proteins), regard-
less of the magnitude of change. This assumed that even
slight variations in the levels of multiple proteins can result
in pathway alterations. Using IPA, the protein changes were
assigned to groups of biological functions in the Ingenuity
knowledge base and z-scores were calculated as a predic-
tion of whether a biological function was either up- or
down-regulated. The biological functions underlying the
identified molecular changes in the NR1neo−/− mouse are
shown in Figure 2A. The frontal cortex showed a decrease
in “coordination”, “long-term potentiation”, and “quantity
of filaments”. To a lesser extent, the behavioural domains
of cognition, learning, and memory were decreased and
hyperactive behaviour was increased. In the hippocampus a
broader range of functions appeared to be affected. The
most prominent finding here was an upregulation in “for-
mation of cellular protrusions”. Full information including
proteins underlying these functions can be found in
(Additional file 4: Table S4). Furthermore, we generated
functional networks using IPA. Both networks suggested
an involvement of the ERK pathway in the two regions.
Functional annotation using the ingenuity upstream ana-
lysis tool revealed an inhibition of this pathway (Figure 2B).
In an attempt to further validate the IPA in silico find-
ings, we carried out a GO-term based protein set enrich-
ment analysis. We analysed whether specific GO terms
reflecting either biological pathways, KEGG pathways, or
cellular compartments were significantly over-represented
in the datasets of significantly altered proteins using
hypergeometric testing (Figure 3). We validated the in-
volvement of “clathrin adaptor complex/coat assembly/
vesicle plasma membrane anchored proteins” and “long-
term potentiation” in the frontal cortex, as well as “energy
Table 1 Analysis of protein levels in serum of NR1neo−/− (n = 12) and wildtype mice (n = 12) using multiplexed
immunoassay
A)
Protein Name UniProt ID Gene name Ratio NR1/Wt P P*
C-C motif chemokine 12 Q62401 Ccl12 ▼ 0.52 0.0002 0.0060
Insulin-like growth factor I (IGF-I) P05017 Igf1 ▼ 0.16 0.0002 0.0060
Osteopontin (2AR) P10923 Spp1 ▼ 0.36 0.0003 0.0060
Interleukin-12 subunit alpha (IL-12A) P43431 IL12A ▲ 1.86 0.0004 0.0060
Vascular endothelial growth factor A (VEGFA) – assay 1 Q00731 Vegfa ▲ 7.41 0.0004 0.0060
– assay 2 ▲ 8.26 0.0006 0.0061
von Willebrand factor (vWF) Q8CIZ8 Vwf ▲ 2.98 0.0005 0.0061
Fibrinogen, alpha polypeptide (Protein Fga) Q99K47 Fga ▲ 13.19 0.0007 0.0061
Apolipoprotein A-I (ApoA1) Q00623 Apoa1 ▲ 16.77 0.0007 0.0061
C-X-C motif chemokine 5 (Cytokine LIX) P50228 Cxcl5 ▼ 0.75 0.0023 0.0143
Eotaxin (C-C motif chemokine 11) P48298 Ccl11 ▼ 0.50 0.0024 0.0143
Lymphotactin (C motif chemokine 1) P47993 Xcl1 ▼ 0.56 0.0025 0.0143
Clusterin (Apolipoprotein J) Q06890 Clu ▼ 0.61 0.0028 0.0152
Macrophage colony-stimulating factor 1 (CSF-1) P07141 Csf1 ▲ 1.65 0.0031 0.0156
Immunoglobulin A (IgA) NA NA ▼ 0.75 0.0035 0.0158
Glutathione S-transferase Mu 1 P10649 Gstm1 ▲ 1.57 0.0036 0.0158
Leptin (Obesity factor) P41160 Lep ▼ 0.49 0.0051 0.0206
C-C motif chemokine 7 (MCP-3) Q03366 Ccl7 ▼ 0.51 0.0052 0.0206
Interleukin-1 beta (IL-1 beta) P10749 IL1B ▼ 0.58 0.0103 0.0358
Adrenocorticotropic hormone (ACTH) P01193 Pomc ▼ 0.58 0.0105 0.0358
Oncostatin-M (OSM) P53347 Osm ▲ 2.15 0.0114 0.0370
Glucagon P55095 Gcg ▲ 1.42 0.0202 0.0612
CC chemokine DC/B-CK (Chemokine (C-C motif) ligand 22) Q546S6 Ccl22 ▼ 0.82 0.0210 0.0612
Interleukin-11 (IL-11) P47873 Il11 ▲ 1.52 0.0212 0.0612
Epidermal growth factor (EGF) – assay 1 P07522 Egf ▲ 2.42 0.0235 0.0654
– assay 2 ▲ 2.12 0.0287 0.0718
Myeloperoxidase (MPO) P11247 Mpo ▲ 1.53 0.0246 0.0659
Tumor necrosis factor (TNF-alpha) P06804 Tnf ▲ 1.66 0.0283 0.0718
Coagulation factor VII P70375 F7 ▼ 0.86 0.0309 0.0748
Neutrophil gelatinase-associated lipocalin (NGAL) P11672 Lcn2 ▲ 3.27 0.0443 0.1038
Endothelin-1 (ET-1) P22387 Edn1 ▼ 0.72 0.0473 0.1075
The table includes Uniprot ID, gene names, ratios (calculated based on average), P values (Mann-Whitney U-test), and adjusted P values (P*, Benjamini-Hochberg
corrected). Significant analytes with an increase/decrease greater than 5-fold are highlighted in bold.
▼ downregulated, ▲ upregulated.
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hippocampus.
Validation of significantly changed functional pathways
As a next step, we focussed on the core identified signifi-
cantly altered pathways and biological functions using
SRM, a highly sensitive targeted proteomic method, as an
orthogonal validation method of the reported results. We
developed an assay panel incorporating proteins involved inthe ERK-pathway, clathrin-mediated endocytosis, gluta-
matergic signal transduction/transport, and energy me-
tabolism. Furthermore, cell-type-specific markers were
included. Using SRM we were able to validate most of
the significantly altered pathways identified by label-free
LC-MSE (Table 2).
In the LC-MSE phase of the study, we were unable to
detect any of the NMDA receptor subunits for quantita-
tive analysis, most likely due to the lower sensitivity of
Frontal Cortex Hippocampus
Figure 1 Volcano plots of group comparisons (10 NR1neo−/− vs. 10 wildtype mice) showing the adjusted significance P value (log2)
versus fold change (log2). The plots indicate the most robust protein changes in the NR1
neo−/−. Horizontal grey lines indicate an adjusted P
value threshold of 0.05, vertical grey dotted lines indicate a fold-change threshold of 10%. Uniprot-identifiers indicate altered proteins. Significant
proteins are quantified by at least two peptides. Full information can be found in Additional file 3: Table S3.
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subunit using SRM and this revealed a significant decrease
in this protein in both the frontal cortex (ratio = 0.26) and
hippocampus (ratio = 0.16). In contrast, no changes in other
glutamate receptors (GluR-1, GluR-2, GluR-3) were de-
tected in either tissue. In the frontal cortex, abnormalities
in neurotransmitter metabolism and transport was indi-
cated through significant abundance changes in the key
enzymes glutamate decarboxylase 2, GABA aminotransfer-
ase, and the vesicular glutamate transporter 1. Furthermore,
clathrin-mediated endocytosis was found to be increased,
oligodendrocytic markers decreased, and long-term po-
tentiation altered. In the hippocampus, an alteration in pur-
ine metabolism could be confirmed as well as changes in
long-term potentiation. The ERK-pathway appeared to be
affected in both frontal cortex and the hippocampus, as
suggested earlier through pathway analysis.
Discussion
Herein, we present the first comprehensive proteomic
study characterising central and peripheral changes in
the NR1neo−/− mouse model. We employed orthogonal
quantitative proteomic approaches to investigate protein
alterations in serum that can serve as surrogate or transla-
tional biomarkers for decreased NMDAR function. The
findings associated with NMDAR hypofunction in hippo-
campus and frontal cortex brain tissue may aid in the
discovery of novel drug targets and in elucidating affected
downstream pathways. Currently, animal models are almost
exclusively assessed using behavioural readouts, leaving
questions as to the underlying cellular and molecular
network alterations unanswered.Using multiplex immuno-profiling to measure peripheral
metabolic, neurotrophic, and immunological factors, we
initially linked the NMDA-mediated glutamatergic hypo-
function to several serum analyte alterations. Interestingly,
eight out of the 29 changing proteins (ApoA1, coagulation
factor-VII, EGF, IGF-1, leptin, TNFα, VEGF, vWF) have pre-
viously been reported as changed in SZ and five (ApoA1,
Eotaxin, EGF, Leptin, TNFα,) in ASD biomarker studies
[50-54]. This supports the notion that serum changes re-
flect aspects of the pathophysiology associated with psychi-
atric disorders; providing evidence for the translational
utility of serum biomarker studies and their potential for
personalised medicine approaches.
The strongest alteration was a 17-fold increase in
levels of the lipid transport protein ApoA1. Although
ApoA1 has not been linked to effects on glutamatergic
signalling before, it is one of the most robust serum bio-
markers in SZ [55,56], despite or whereas or even
though this has been mainly found to be decreased in
CSF, brain, and peripheral tissues of patients. The reason
for this apparent discrepancy may be due to adaptive re-
sponses which are specific to the NR1neo−/− mouse
model. ApoA1 plays a role in cholesterol transport and
has been shown to prevent learning and memory deficits
in an Alzheimer’s disease mouse model by attenuating
neuroinflammation [57]. We also found similar strong
increases in fibrinogen, implicating alterations in the
blood coagulation system, as well as VEGF, which is pro-
duced by neuronal and glial cells in the developing ner-
vous system and directly stimulates neuronal functions
such as neurogenesis and cell survival in culture and
in vivo [58]. This might be linked to our findings in
Figure 2 Computational pathway analysis of brain proteomic profiling. (A) IPA showing decreased and increased biological functions in
NR1neo−/− mouse brain regions. Depicted are functions with an activation score (z-score) >1 (increased activation) or < −1 (decreased activation)
with their corresponding log2 (P) (right graph, the dotted line represents the 0.05 P value threshold) as well as the five most-significantly
dysregulated non-directionally (z-score > −1, <1, or not predicted) affected pathways (in the middle of the bar plots). (B) Identified IPA networks
in the data set by global pathway analysis using the Ingenuity Pathways Knowledge Database (IPKB) software. All significantly altered proteins in
the frontal cortex and hippocampus from the model were used for the network analysis based on criteria annotated in the IPKB database, which
contains molecular information available in the scientific literature. Networks were generated algorithmically on the basis of the connectivity
derived from molecular interaction information, scored according to the significant number of focus proteins and assigned associated biological
functions (see network descriptions) by overlaying the network molecules onto predefined maps of functional or pathway information in the IPKB
database. Proteins are indicated by their gene names. Red and green symbols/text indicate increased and decreased proteins, respectively. Blue
symbols indicate predicted inhibition, orange lines indicate predicted activation. Yellow lines indicate inconsistencies with the states of the
downstream molecules. Lines ending with arrows indicate activation, lines without arrows indicate interaction/binding.
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indicating increased neuro- and synaptogenesis, which was
confirmed by LC-MSE, SRM, and computational pathwayanalysis (Table 2). Synapse formation, maintenance, and
plasticity are critical for the correct function of the nervous







































Figure 3 Functional enrichment analysis of significantly changed proteins in frontal cortex and hippocampus of the NR1neo−/− mouse.
Proteins were divided into fold-change bins for separate analyses. Colour coded z-score transformed P values indicate the significance of the
enrichment for each bin as indicated. Representative enriched GO terms are annotated. Pathways highlighted in yellow overlapped with the IPA
biofunction analysis, asterisks indicate pathways included in the SRM assay validation.
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circuitry. In parallel with the increased synaptic markers,
we found an increase in proteins involved in neurotrans-
mitter metabolism and transport in the frontal cortex.
These findings provide further evidence for increased excit-
ability and imbalance in the frontal cortex, resembling
neurochemical changes which are characteristic of SZ
[59,60], ASD [61-64], and other disorders with negative
symptom domains. At the mechanistic level, VEGF has
been shown to exert its neurotrophic properties by regulat-
ing NMDAR activity via the SRC family kinase (SFK) path-
way [65]. The SFK pathway stimulates signalling
events in neuronal cell types, including activation of
phospholipase C-gamma, AKT, and ERK. We found
abnormal ERK signalling in both brain regions.
Therefore, further studies are warranted to investi-
gate the connection of NMDAR and VEGF signalling.
Our findings suggest that one or more components of the
VEGF signalling pathway might constitute a new thera-
peutic target for the treatment of SZ and potentially other
psychiatric disorders.
This is also the first study linking NMDA-mediated
glutamate dysfunction to decreased serum levels of IGF-
1. At the circulatory level, IGF-I promotes cell differ-
entiation and growth and may also function as an
anti-apoptotic agent [66]. Lower levels of IGF-1 havebeen found in serum of antipsychotic-naive [67] and
antipsychotic-treated SZ patients [68], as well as in chil-
dren with ASD [69-71]. A recent study reported a rela-
tionship between negative symptoms and IGF-1 plasma
levels in first episode SZ [72]. Centrally, IGF-1 plays a
major role in early brain development, neuro- and syn-
aptogenesis, secretion of various neurotransmitters and
myelination processes [73-75]. Remarkably, IGF-1 treat-
ment restores synaptic deficits in neurons from 22q11.2
deletion syndrome patients, a syndrome characterized by
an increased risk of SZ and ASD [76], as well as in a
SHANK3-deficient mouse model of autism [77]. Thus,
we suggest that drugs which target the IGF-1 pathway
should be evaluated for the treatment of psychiatric dis-
orders associated with impaired glutamate function. One
limitation of the multiplex immunoassay profiling stage
of the study is the potential bias in the selection and the
molecular class assignment of the investigated mole-
cules. These assays were based on commercial availabil-
ity and therefore only targeted selected classes of
regulatory molecules. Therefore, it is possible that a dif-
ferent selection of molecules would lead to different
conclusions from those drawn in this study.
Possibly reflecting IGF-1 function, we found an in-
crease in synaptic markers in the frontal cortex and de-
creased levels of myelin-specific proteins in the frontal
Table 2 Significantly changed proteins identified using label-based LC-SRM in the frontal cortex and hippocampus of the NR1neo−/− (n = 12) compared to
wildtype mice (n = 12)
Frontal Cortex Hippocampus
Biological Pathway/Function UP-ID Gene name M TPP Ratio
NR1/Wt




Pathway analysis (LC-MSE) not annotated
PSEA: ▲ Purine metabolism
IPA: ▲ Concentration of ATP
Hypoxanthine-guanine phosphoribosyltransferase P00493 Hprt1
3 5|4
not significant
4|4 1.24 ▲ 0.0054 0.018
1 4|5 6|4 1.22 ▲ 1.8 × 10-15 1.4 × 10-14
Glycolysis/Gluconeogenesis/Tricarbon acid cycle
Pathway analysis (LC-MSE)
IPA: Metabolism of NADH
PSEA: TCA cycle
Aspartate aminotransferase, mito. P05202 Got2
3 5|4 1.15 ▲ 3.5 × 10-05 4.4 × 10-04 5|7 1.15 ▲ <×10-16 <×10-16
1 5|7 1.12 ▲ 8.9 × 10-16 1.1 × 10-14 5|5 1.18 ▲ 1.2 × 10-07 7.1 × 10-07
Pyruvate kinase, mito.
P52480 Pkm
3 4|5 1.17 ▲ 0.0007 0.0059 4|5 1.26 ▲ 1.3 × 10-06 8.3 × 10-06
▲***
2 5|7 1.13 ▲ 1.4 × 10-08 1.6 × 10-07 4|7 1.07 ▲ 0.0028 0.0158
NADH-ubiquinone oxidoreductase 75 kDa subunit, mito. Q91VD9 Ndufs1 1 4|4 1.18 ▲ 0.001 0.005 8|4 1.28 ▲ <×10-16 <×10-16
Neurotransmitter metabolism/transport
Pathway analysis (LC-MSE)
IPA: Transport of amino acids
not annotated
IPA: Transport of L-glutamic acid






Catechol O-methyltransferase O88587 Comt 1 4|2 not significant 3|3 not significant
Glutamate decarboxylase 2 P48320 Gad2 2 3|4 1.25 ▲ 0.0004 0.0015 3|4 not significant
Vesicular glutamate transporter 1 (VGluT1) Q3TXX4 Slc17a7
3 5 1.14 ▲ 0.0031 0.0192 5 not significant
1 6 1.20 ▲ <×10-16 <×10-16 4|6 not significant
4-aminobutyrate aminotransferase, mito P61922 Abat 2 4|6 1.14 ▲ 0.0006 0.0024 4|5 not significant
Clathrin-mediated exo-/endocytosis
Pathway analysis (LC-MSE)
PSEA:▲ Vesicle coating, ▲ Membrane budding
not annotated
PSEA: ▲ Clathrin coated pit etc.
IPA: ▲ Formation of artificial clathrin cages
AP-2 complex subunit alpha-1 P17426 Ap2a1 1 5|6 1.13 ▲ 6.5 × 10-08 5.2 × 10-07 6|6 not significant ▲*
Synaptojanin Q8CHC4 Synj 2 3|5|3 1.08 ▲ 0.017 0.041 5|5|5 not significant
Synapsin-1 O88935 Syn1 2 6|4|3 1.11 ▲ 0.005 0.016 6|4|3 not significant




















Table 2 Significantly changed proteins identified using label-based LC-SRM in the frontal cortex and hippocampus of the NR1neo−/− (n = 12) compared to
wildtype mice (n = 12) (Continued)
Neurotransmitter receptors
N-methyl-D-aspartate receptor subunit NR1 P35438 Grin1 3 6 0.26 ▼ <×10-16 <×10-16 3|2 0.16 ▼ <E-16 <E-16
Glutamate receptor 1 (GluR-1) P23818 Gria1 3 4|3 not significant 4 not significant
Glutamate receptor 2 (GluR-2) P23819 Gria2 3 5|4|4|4 not significant 4|3 not significant
Glutamate receptor 3 (GluR-3) Q9Z2W9 Gria3 3 4|2 not significant 3|4|3|4 not significant
Long-term potentiation/Signal transduction
Pathway analysis (LC-MSE)
IPA: ▼Long term potentiation (of synapse) IPA: ▼ Long term potentiation
PSEA: ▼ Long term potentiation
PSEA:▼ EBB-signalling pathway
CaM kinase II subunit alpha P11798 Camk2a 3 3|4 0.90 ▼ 0.0006 0.0056 ▼*** 3|5 not significant ▼*
CaM kinase II subunit beta P28652 Camk2b
1 6|6
not significant
6|6 0.89 ▼ 1.5 × 10-08 1.2 × 10-07
2 6|6 6|6 0.96 ▼ 3.6 × 10-05 1.7 × 10-04
3 5|4 6|7 0.89 ▼ 1.5 × 10-08 1.2 × 10-07
CaM kinase II subunit gamma Q923T9 Camk2g 3 4|4 not significant ▼*** 4|4 not significant
Calcineurin subunit B type 1 Q63810 Ppp3r1 2 6|6 0.90 ▼ 0.0002 0.001 7|6 not significant
Ser/thr-protein phosphatase 2B cat. subunit β P48453 Ppp3cb 2 5|2 1.11 ▲ 0.012 0.032 5|2 not significant
Neurochondrin Q9Z0E0 Ncdn
3 4|3 1.21 ▲ 0.017 0.083 4|4
not significant
1 4|3 1.16 ▲ 0.001 0.005 3|3 ▼**
Disks large homolog 4 (PSD-95) Q62108 Dlg4
3 5|4 not significant 4|5 1.18 ▲ 0.0004 0.0015
1 4|3 1.15 ▲ 0.0032 0.0099 4|3 not significant
ERK-Pathway
Pathway analysis IPA: Implicated in top network IPA: Implicated in top network
Astrocytic phosphoprotein PEA-15 Q62048 Pea15
3 5|4 1.09 ▲ 0.10 0.33 6|4 1.12 ▲ 0.007 0.021 ▲(*)
1 8 1.12 ▲ 0.001 0.005 8|9 1.20 ▲ <×10-16 <×10-16
Mitogen-activated protein kinase 1 (ERK-2 ) P63085 Erk2
3 5|5 1.07 ▲ 0.04 0.13 6|5 1.12 ▲ 0.0002 0.0009
2 4|6|6 1.16 ▲ 9.8 × 10-10 1.7 × 10-08 4|6|6 0.94 ▲ 0.0202 0.0685




















Table 2 Significantly changed proteins identified using label-based LC-SRM in the frontal cortex and hippocampus of the NR1neo−/− (n = 12) compared to
wildtype mice (n = 12) (Continued)
Actin cytoskeleton/cell morphology/structural elements
Pathway analysis (LC-MSE)
amongst others: IPA: ▼ Organisation of cytoskeleton IPA: ▲ Formation plasma membrane projections
IPA:▼ Organisation of cytoplasm IPA: ▲ Microtubuli dynamics
IPA: Degeneration of axons IPA: ▲ Organisation of cytoskeleton
PSEA: ▲ Neuronal projection membrane IPA: ▲Organisation of cellular protrusions
PSEA: ▲ Regulation of synaptic plasticity
PSEA: ▲ Neg. regulation of cell differentiation
PSEA: ▲ Neg. regulation of cell death/apoptosis
PSEA: ▼ Extracellular matrix/space
Myristoylated alanine-rich C-kinase substrate P26645 Marcks
2 6|2|4 1.22 ▲ 8.4 × 10-05 5.7 × 10-04
▲***
4|4|6 1.41 ▲ 1.1 × 10-08 1.1 × 10-07
▲(*)
3 4|4|6 not significant 6|3|4 1.32 ▲ 2.3 × 10-10 8.0 × 10-09
PKC and casein kinase substrate in neurons protein 1 Q61644 Pacsin1 3 6|4 not significant 6|3 1.28 ▲ 2.9 × 10-09 3.6 × 10-08 ▼**
Methionine aminopeptidase 2 (MAP 2) O08663 Metap2 3 5|4 not significant 5|3 1.28 ▲ 1.6 × 10-07 1.1 × 10-06
Neurofilament light polypeptide (NF-L) P08551 Nefl 2 3|4|3 not significant 3|4|3 1.13 ▲ 0.0010 0.0086
Vesicle-fusing ATPase P46460 Nsf
3 5|6|6 1.07 ▲ 0.008 0.047 5|6|5 1.10 ▲ 0.0005 0.0018
2 6|5|4 1.10 ▲ 2.0 × 10-07 1.7 × 10-06 6|5|4 not significant
Neuromodulin (Axonal membrane protein GAP-43) P06837 Gap43 2 5|6 1.21 ▲ 0.008 0.022 6 1.21 ▲ 0.008 0.038
Neural cell adhesion molecule 1 (N-CAM-1) P13595 Ncam1 2 6|5|3 1.11 ▲ 0.0003 0.001 6|5|3 1.11 ▲ 0.0003 0.003
2’,3’-cyclic-nucleotide 3’-phosphodiesterase (CNPase) P16330 Cnp 3 5|3|3 0.84 ▼ 0.024 0.108 4|3|5 not significant ▼*
Myelin basic protein (MBP) P04370 Mbp
3 5 0.87 ▼ 1.7 × 10-05 0.0003 5 not significant
2 5 not significant 5 0.93 ▼ 0.0127 0.0479
Myelin proteolipid protein (PLP) P60202 Plp1
3 5|4|4 0.87 ▼ 1.2 × 10-07 3.0 × 10-06
▼***
5|4|4 1.11 ▲ 0.0001 0.0005
▼*
2 6|7|7 0.87 ▼ <×10-16 <×10-16 6|7|6 0.96 ▼ 0.0123 0.0479
Glial fibrillary acidic protein (GFAP) P03995 Gfap 3 3|4 1.23 ▲ 0.002 0.017 3|4 1.29 ▲ 1.8 × 10-06 9.9 × 10-06 ▲*
Coronin-1A (Coronin-like protein A) O89053 Coro1a 1 5|5 1.11 ▲ 0.003 0.010 5|5 not significant
IPA, Ingenuity pathway analysis; PSEA, Protein set enrichment analysis; UP-ID, uniprot-ID; M, method (assays were split into three methods); TPP, transitions per peptide; G, specific for glutamatergic neurons; B, specific
for GABA-ergic neurons; N, specific for neurons; O, oligodendrocyte specific; A, astrocyte specific; M, microglia specific; ▲, increased, ▼, decreased. *, **, and *** ≤0.05, 0.01, and 0.001, respectively. P values were




















Wesseling et al. Molecular Autism 2014, 5:38 Page 13 of 17
http://www.molecularautism.com/content/5/1/38cortex and to a lesser extent in the hippocampus
(Table 2). Myelin integrity is crucial for functional
neuro-circuitry and perturbations in myelin either dur-
ing or after neuronal development leads to neurological
deficits [78]. The findings are consistent with reports of
abnormal myelination in BA10 of SZ, BD [79], and ASD
patients [71,80]. Interestingly, effects on glutamate sig-
nalling have already been linked to oligodendrocyte dys-
function. Rat brains exposed prenatally to the NMDAR
antagonist phencyclidine show reduced levels of oligo-
dendrocyte progenitors [81], resulting in fewer differen-
tiated mature oligodendrocytes capable of producing
myelin. Our results provide further evidence of the role
of glutamate and its receptors in white matter abnormal-
ities and dysfunction in neurodevelopmental and psychi-
atric disorders.
Serum profiling also identified an overall decrease in
chemokines (Table 1) generally associated with an anti-
inflammatory status reflective of an anti-oxidative state
[82], which is supported by an increase in glutathione S-
transferase levels in the NR1neo−/− model. Centrally, che-
mokine signalling regulates essential processes for the
establishment of neural networks such as neuronal mi-
gration and axon wiring [83]. Decreased chemokine
functioning has been linked to deficits in social inter-
action and an increased repetitive behaviour phenotype,
as reported in ASD and other neuropsychiatric disorders
[84]. Furthermore, we detected decreased levels of lep-
tin. Leptin facilitates hippocampal synaptic plasticity via
enhanced NMDAR-mediated Ca2+-influx [85]. Impair-
ment of this process might contribute to the cognitive
deficits by inducing rapid alterations in hippocampal
dendritic morphology and synaptic density [85].
The brain proteomic profiling study also highlights a
link between NMDAR and purinergic signalling by
identifying corresponding alterations in the hippocam-
pus (Table 2 and Figure 3). Purines play a major role in
neurotransmission and neuromodulation with their ef-
fects being mediated by the purine and pyrimidine
receptor subfamilies P1, P2X, and P2Y. Purinergic sig-
nalling is associated with learning and memory [86,87]
and locomotor activity, in line with the hippocampal
specificity observed in our analysis. At a clinical level, it
has been shown that antipsychotics, such as haloperidol,
chlorpromazine, and fluspirilen, inhibit ATP-evoked re-
sponses mediated by P2X receptors [88,89]. Hypotheses
of dysfunctional purinergic signalling have been put
forward for psychiatric disorders [90] and ASD [91].
Applied to a maternal immune activation mouse model
of ASD, anti-purinergic therapy has been found to
reverse core social deficits and sensorimotor coordin-
ation abnormalities while, at the same time, normalizing
ERK1/2 and CAMK2 signal transduction abnormal-
ities [92]. ERK1/2 and CamK2 pathways are essentialcomponents of NMDAR-related signal transduction and
were found to be increased, resp. decreased in the
NR1neo−/− mouse.
The ERK signalling pathway comprises phosphoryl-
ation of proteins involved in transcriptional and
translational regulation, dendritic arborisation, cellular
excitability, long-term potentiation and depression,
neuronal survival, synaptogenesis, and neurotransmitter
release [93], and our findings indicated that all of these
pathways were altered in the NR1neo−/− mouse. Up-
stream, ERK activation is regulated by the activity of
dopamine, serotonin, and glutamate receptors [94],
which are modulated by antipsychotics [95]. Antipsy-
chotics have been shown to differentially mediate the
ERK cascade in vitro and in vivo, dependent on cell and
tissue type [96-99]. Clozapine differs from all other anti-
psychotics by recruiting the EGF-receptor to signal to
ERK [100,101], which contributes to clozapine’s broad
clinical phenotype. Consistent with this, we found evi-
dence for elevated serum levels of EGF. Further evi-
dence for the involvement of ERK signalling in the
pathogenesis of psychiatric spectrum is provided by post
mortem brain studies [102,103]. The ERK signalling
pathway has also been implicated in the mechanism of
action of mood stabilizers [104] and social behaviour
[105], and extensively for ASD [106,107]. Interestingly,
clozapine has also been shown to be efficacious in the
treatment of ASD patients [108]. Remarkably, a recent
study showed that the transcriptional regulation exerted
by a diverse set of ASD-associated genes (FMR1, TSC1,
PTEN, etc.) converges on ERK signalling [109].
With this comprehensive proteomic investigation, we
found that the knockdown of one single protein can lead to
multiple alterations in a range of signalling pathways both
in the central nervous system as well as in blood serum. In
brain tissue, we found pyruvate kinase to be one of the
most robust changes in the NR1neo−/− mouse, consistent
with studies showing increased levels of this key glycolytic
enzyme in SZ [110] and in a phencylidine rat model [111].
Furthermore, we found decreased levels of CamKIIa, which
is associated with cognitive impairment [112]. Another
prominent change was a 20 to 30% increase in MARCS in
both regions. MARCS, regulated by calcium-calmodulin
and PKC signalling, is a filamentous actin-crosslinking pro-
tein involved in cytoskeleton remodelling [113]. Hence, it is
involved in the maintenance of dendritic spines and con-
tributes to PKC-dependent morphological plasticity [114]
and memory function [115,116]. Furthermore, MARCS is
specifically degraded in response to intense NMDAR
stimulation. Since the NR1neo−/− mouse expresses only 10%
of the NR1 subunit, less NMDAR can be stimulated com-
pared to the WT. This is consistent with our results of in-
creased MARCS levels in the NR1neo−/− model [117].
MARCS has been implicated in proteomic studies of SZ
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sociated with both lithium and valporate treatment [118].
Conclusions
In summary, our results provide the first proteomic
characterization of the NR1neo−/− mouse model to date,
investigating both brain and serum changes associated
with NMDAR hypofunction. We provide evidence for a
strong link of neurotransmitter dysfunction and changes
in circulating bioactive peptides and proteins, which are
implicated in altered brain function and synaptic re-
modelling. The results presented here provide novel in-
sights into the molecular consequences of altered
NMDAR function, such as SZ and ASD, and into the as-
sumed disease mechanisms of psychiatric disorders in
which perturbations of NMDAR function are likely to
play an important role.
Taken together, the current findings provide further
support that neuropsychiatric disorders present with
prominent systemic changes affecting a wide range of
tissues outside the brain which could represent diagnos-
tic and surrogate markers for personalised medicine ap-
proaches in the field of psychiatry.
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